247 related articles for article (PubMed ID: 31060375)
1. Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance.
Lustberg MB; Reinbolt R; Addison D; Ruppert AS; Moore S; Carothers S; Suresh A; Das H; Berger M; Ramaswamy B; Wesolowski R; Binkley P; Raman SV; Shapiro CL
Circ Cardiovasc Imaging; 2019 May; 12(5):e008777. PubMed ID: 31060375
[No Abstract] [Full Text] [Related]
2. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.
Jordan JH; D'Agostino RB; Hamilton CA; Vasu S; Hall ME; Kitzman DW; Thohan V; Lawrence JA; Ellis LR; Lash TL; Hundley WG
Circ Cardiovasc Imaging; 2014 Nov; 7(6):872-9. PubMed ID: 25273568
[TBL] [Abstract][Full Text] [Related]
3. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.
Ferreira de Souza T; Quinaglia A C Silva T; Osorio Costa F; Shah R; Neilan TG; Velloso L; Nadruz W; Brenelli F; Sposito AC; Matos-Souza JR; Cendes F; Coelho OR; Jerosch-Herold M; Coelho-Filho OR
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1045-1055. PubMed ID: 30092965
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors.
Jordan JH; Vasu S; Morgan TM; D'Agostino RB; Meléndez GC; Hamilton CA; Arai AE; Liu S; Liu CY; Lima JA; Bluemke DA; Burke GL; Hundley WG
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27502058
[TBL] [Abstract][Full Text] [Related]
7. Early Changes in Myocardial Mechanics Detected by 3-Dimensional Speckle Tracking Echocardiography in Patients Treated With Low Doses of Anthracyclines.
Piveta RB; Rodrigues ACT; Vieira MLC; Fischer CH; Afonso TR; Daminello E; Cruz FM; Galvão TFG; Katz M; Morhy SS
JACC Cardiovasc Imaging; 2018 Nov; 11(11):1729-1731. PubMed ID: 29909102
[No Abstract] [Full Text] [Related]
8. Characterization of the Changes in Cardiac Structure and Function in Mice Treated With Anthracyclines Using Serial Cardiac Magnetic Resonance Imaging.
Farhad H; Staziaki PV; Addison D; Coelho-Filho OR; Shah RV; Mitchell RN; Szilveszter B; Abbasi SA; Kwong RY; Scherrer-Crosbie M; Hoffmann U; Jerosch-Herold M; Neilan TG
Circ Cardiovasc Imaging; 2016 Dec; 9(12):. PubMed ID: 27923796
[TBL] [Abstract][Full Text] [Related]
9. Progressive 3-Month Increase in LV Myocardial ECV After Anthracycline-Based Chemotherapy.
Meléndez GC; Jordan JH; D'Agostino RB; Vasu S; Hamilton CA; Hundley WG
JACC Cardiovasc Imaging; 2017 Jun; 10(6):708-709. PubMed ID: 27544895
[No Abstract] [Full Text] [Related]
10. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
[TBL] [Abstract][Full Text] [Related]
11. Identification of anthracycline cardiotoxicity: left ventricular ejection fraction is not enough.
Eidem BW
J Am Soc Echocardiogr; 2008 Dec; 21(12):1290-2. PubMed ID: 19041570
[No Abstract] [Full Text] [Related]
12. The early variation of left ventricular twisting function in patients with lymphoma received anthracycline therapy assessed by three-dimensional speckle tracking echocardiography.
Song F; Kang Y; Zhang C; Xu Y; Shi J; Guo Y; Zhang Q; Shu X; Cheng L
Cardiol J; 2017; 24(5):484-494. PubMed ID: 28353310
[TBL] [Abstract][Full Text] [Related]
13. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.
Ohtani K; Fujino T; Ide T; Funakoshi K; Sakamoto I; Hiasa KI; Higo T; Kamezaki K; Akashi K; Tsutsui H
Clin Res Cardiol; 2019 Jun; 108(6):600-611. PubMed ID: 30367208
[TBL] [Abstract][Full Text] [Related]
14. Two- and three-dimensional myocardial strain imaging in the interrogation of sex differences in cardiac mechanics of long-term survivors of childhood cancers.
Li VW; Liu AP; So EK; Ho KK; Yau JP; Cheuk DK; Cheung YF
Int J Cardiovasc Imaging; 2019 Jun; 35(6):999-1007. PubMed ID: 30848401
[TBL] [Abstract][Full Text] [Related]
15.
Laursen AH; Thune JJ; Hutchings M; Hasbak P; Kjaer A; Elming MB; Ripa RS
Clin Physiol Funct Imaging; 2018 Mar; 38(2):176-185. PubMed ID: 28251781
[TBL] [Abstract][Full Text] [Related]
16. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Native Myocardial T1 Mapping for Early Detection of Anthracycline-Induced Cardiotoxicity in Patients with Cancer: a Systematic Review and Meta-analysis.
Mohamed AA; Elmancy LY; Abulola SM; Al-Qattan SA; Mohamed Ibrahim MI; Maayah ZH
Cardiovasc Toxicol; 2024 Jun; 24(6):563-575. PubMed ID: 38700665
[TBL] [Abstract][Full Text] [Related]
20. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study.
Gong IY; Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Graham JJ; Chow CM; Thavendiranathan P; Dai D; Ng MY; Barfett JJ; Connelly KA; Yan AT
Int J Cardiovasc Imaging; 2019 Apr; 35(4):653-662. PubMed ID: 30390170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
